Clinical Trial Update: A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating neoadjuvant SHR6390 with anastrozole, pyrotinib, and trastuzumab in ER+/HER2+ breast cancer is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Pyrotinib (pyrotinib)
• SHR6390 (SHR6390)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN